---
figid: PMC9471148__fonc-12-927587-g002
figtitle: An overview of agents and treatments for PDGFRA-mutated gastrointestinal
  stromal tumors
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC9471148
filename: fonc-12-927587-g002.jpg
figlink: /pmc/articles/PMC9471148/figure/f2/
number: F2
caption: PDGF/PDGFRA signaling pathways and agent treatments. In PDGFRA mutaled GIST.
  PDGF isoforms bind to the related PDGFRs, initiate distinct receptor dimerization
  and phosphorylation, thereby activating various signaling pathways including the
  RAS-MEK-MAPK, PI3K-mTOR, JAK/STAT, and Notch pathway PDGFR antibodies such as INC-3G3,
  MEDI-575 and the specific RNA aptamer PDR3 can selectively bind to PDGFRA, after
  binding, these antibodies or aptamers can inhibit the downstream pathways. Activation
  or inhibition of these pathways influences cellular proliferation, angiogenesis,
  and apoptosis. PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth
  factor receptor; PKC, protein kinase C; PI3K, phosphati-dylinositol 3 kinase; AKT/PKB,
  protein kinase B; JAK, Janus kinase; STAT, signal transducers and activators of
  transcription; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated
  protein kinase; PDR3, the specific RNA aptamer.
papertitle: An overview of agents and treatments for PDGFRA-mutated gastrointestinal
  stromal tumors.
reftext: Yingchao Sun, et al. Front Oncol. 2022;12:927587.
year: '2022'
doi: 10.3389/fonc.2022.927587
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.
keywords: PDGFRA mutation | targeted therapy | avapritinib | ripretinib | crenolanib
  | gastrointestinal stromal tumors (GIST)
automl_pathway: 0.9355177
figid_alias: PMC9471148__F2
figtype: Figure
redirect_from: /figures/PMC9471148__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9471148__fonc-12-927587-g002.html
  '@type': Dataset
  description: PDGF/PDGFRA signaling pathways and agent treatments. In PDGFRA mutaled
    GIST. PDGF isoforms bind to the related PDGFRs, initiate distinct receptor dimerization
    and phosphorylation, thereby activating various signaling pathways including the
    RAS-MEK-MAPK, PI3K-mTOR, JAK/STAT, and Notch pathway PDGFR antibodies such as
    INC-3G3, MEDI-575 and the specific RNA aptamer PDR3 can selectively bind to PDGFRA,
    after binding, these antibodies or aptamers can inhibit the downstream pathways.
    Activation or inhibition of these pathways influences cellular proliferation,
    angiogenesis, and apoptosis. PDGF, platelet-derived growth factor; PDGFR, platelet-derived
    growth factor receptor; PKC, protein kinase C; PI3K, phosphati-dylinositol 3 kinase;
    AKT/PKB, protein kinase B; JAK, Janus kinase; STAT, signal transducers and activators
    of transcription; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated
    protein kinase; PDR3, the specific RNA aptamer.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - RPS6KB1
  - RPS6KB2
  - EIF4EBP1
  - PDGFRA
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - STAT2
  - STAT1
  - STAT3
  - SOAT1
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - NF1
  - KRAS
  - HRAS
  - NRAS
  - BRAF
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - KIT
---
